Literature DB >> 31037567

Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance.

Koichi Soga1,2, Kenji Itani3.   

Abstract

A 47-year-old Japanese man was diagnosed with pancolitis-type ulcerative colitis. He was treated with mesalamine in a pH-dependent release form. On day 16 of administration, he was admitted because of fever and abdominal pain. We diagnosed his symptoms to be the side effects of mesalamine. Hyposensitization using unmodified and a time-dependent release form mesalamine was performed. On day 7 of mesalamine hyposensitization, a colonoscopy was performed. The patient presented with the same allergic symptoms 9 h after the administration of an oral sodium phosphate solution. Eventually, he was orally administered a course of salazosulfapyridine (SASP) at an initial dose of 2.5 mg/day, which was increased to 2000 mg/day. It is generally recognized that SASP intolerance is an indication to switch from SASP to mesalamine. The need to switch treatment from mesalamine to SASP is, therefore, rare because allergic reactions to mesalamine do not occur frequently. We report a very rare case which was presented with abdominal pain and myalgia because of intolerance to mesalamine in whom hyposensitization with and introduction of SASP were successful.

Entities:  

Keywords:  Mesalamine; Oral sodium phosphate solution; Salazosulfapyridine; Ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 31037567     DOI: 10.1007/s12328-019-00985-9

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  19 in total

1.  Oral desensitization to 5-ASA.

Authors:  S Varela; M S Díez; C Gonzalez; C Gonzalez de la Cuesta; L Arenas; R Feijoó; M Menéndez
Journal:  Allergy       Date:  2002-04       Impact factor: 13.146

2.  Adverse events of IBD therapies.

Authors:  Maria Lia Scribano
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

3.  Adverse effects with oral 5-aminosalicyclic acid.

Authors:  J M Fardy; D A Lloyd; R P Reynolds
Journal:  J Clin Gastroenterol       Date:  1988-12       Impact factor: 3.062

4.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

5.  Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.

Authors:  B I Korelitz; D H Present; P H Rubin; S E Fochios
Journal:  J Clin Gastroenterol       Date:  1984-02       Impact factor: 3.062

Review 6.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

Review 7.  Sulfasalazine and 5-ASA compounds.

Authors:  H Allgayer
Journal:  Gastroenterol Clin North Am       Date:  1992-09       Impact factor: 3.806

8.  Exacerbation of chronic ulcerative colitis with mesalamine.

Authors:  J B Sturgeon; P Bhatia; D Hermens; P B Miner
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

9.  Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine.

Authors:  M L Hautekeete; N Bourgeois; P Potvin; L Duville; H Reynaert; G Devis; M Adler; G Klöppel
Journal:  Gastroenterology       Date:  1992-12       Impact factor: 22.682

10.  The role of mesalamine in the treatment of ulcerative colitis.

Authors:  Raffi Karagozian; Robert Burakoff
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.